Harrow, Inc. (HROW)

Market Cap	838.59M
Revenue (ttm)	199.61M
Net Income (ttm)	-17.48M
Shares Out	35.65M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	48.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	520,265
Open	23.31
Previous Close	24.06
Day's Range	22.50 - 23.89
52-Week Range	9.86 - 59.23
Beta	0.45
Analysts	Strong Buy
Price Target	58.40 (+148.3%)
Earnings Date	May 12, 2025

About HROW

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye dr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 382
• Stock Exchange: NASDAQ
• Ticker Symbol: HROW
• Website: https://www.harrow.com

Financial Performance

In 2024, Harrow's revenue was $199.61 million, an increase of 53.32% compared to the previous year's $130.19 million. Losses were -$17.48 million, -28.39% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $58.4, which is an increase of 148.30% from the latest price.

Price Target

$58.4

(148.30% upside)

Analyst Consensus: Strong Buy